Network Pharmacology-Based Study on the Mechanism of Gegen Qinlian Decoction against Colorectal Cancer

الملخص EN

Purpose.

Gegen Qinlian decoction (GQD) has been used to treat gastrointestinal diseases, such as diarrhea and ulcerative colitis (UC).

A recent study demonstrated that GQD enhanced the effect of PD-1 blockade in colorectal cancer (CRC).

This study used network pharmacology analysis to investigate the mechanisms of GQD as a potential therapeutic approach against CRC.

Materials and Methods.

Bioactive chemical ingredients (BCIs) of GQD were collected from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database.

CRC-specific genes were obtained using the gene expression profile GSE110224 from the Gene Expression Omnibus (GEO) database.

Target genes related to BCIs of GQD were then screened out.

The GQD-CRC ingredient-target pharmacology network was constructed and visualized using Cytoscape software.

A protein-protein interaction (PPI) network was subsequently constructed and analyzed with BisoGenet and CytoNCA plug-in in Cytoscape.

Gene Ontology (GO) functional and the Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway enrichment analysis for target genes were then performed using the R package of clusterProfiler.

Results.

One hundred and eighteen BCIs were determined to be effective on CRC, including quercetin, wogonin, and baicalein.

Twenty corresponding target genes were screened out including PTGS2, CCNB1, and SPP1.

Among these genes, CCNB1 and SPP1 were identified as crucial to the PPI network.

A total of 212 GO terms and 6 KEGG pathways were enriched for target genes.

Functional analysis indicated that these targets were closely related to pathophysiological processes and pathways such as biosynthetic and metabolic processes of prostaglandins and prostanoids, cytokine and chemokine activities, and the IL-17, TNF, Toll-like receptor, and nuclear factor-kappa B (NF-κB) signaling pathways.

Conclusion.

The study elucidated the “multiingredient, multitarget, and multipathway” mechanisms of GQD against CRC from a systemic perspective, indicating GQD to be a candidate therapy for CRC treatment.